CancerPPD

This page gives details of Query peptides and provides facility to browse the same in CancerPPD database. Please wait while data is being retrieved. For more information see HELP page.

ID	PMID	SEQUENCE	NAME	LENGTH	ACTIVITY
1103	18617323	RAGLQFPVGRLLRRLLRRLLR	Buforin IIb	21	IC₅₀=11.2 µg/ml
1104	18617323	RAGLQFPVGRLLRRLLRRLLR	Buforin IIb	21	IC₅₀=14.6 µg/ml
1105	18617323	RAGLQFPVGRLLRRLLRRLLR	Buforin IIb	21	IC₅₀=13.2 µg/ml
1106	18617323	RAGLQFPVGRLLRRLLRRLLR	Buforin IIb	21	IC₅₀=17.6 µg/ml
1107	18617323	RAGLQFPVGRLLRRLLRRLLR	Buforin IIb	21	IC₅₀=12 µg/ml
1108	18617323	RAGLQFPVGRLLRRLLRRLLR	Buforin IIb	21	IC₅₀=12.7 µg/ml
1233	7849420	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL	Cecropin B	35	IC₅₀=25.5 µM
1234	7849420	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL	Cecropin B	35	IC₅₀=>100 µM
1237	7849420	SWLSKTAKKLENSAKKRISEGIAIAIQGGPR	Cecropin P1	31	IC₅₀=>100 µM
1238	7849420	SWLSKTAKKLENSAKKRISEGIAIAIQGGPR	Cecropin P1	31	IC₅₀=>100 µM
1241	7849420	MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG	Shiva-1	38	IC₅₀=49.3 µM
1242	7849420	MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG	Shiva-1	38	IC₅₀=>100 µM
1245	7849420	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL	Cecropin B	35	IC₅₀=33.5 µM
1247	7849420	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL	Cecropin B	35	IC₅₀=37 µM
1249	7849420	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL	Cecropin B	35	IC₅₀=>100 µM
1255	10951191	GLFDIIKKIAESF	Aurein1.2	13	LC₅₀ = 10 µM
1264	10951191	GLFDIVKKVVGAFGSL	Aurein2.5	16	LC₅₀=10-100 µM
1273	10951191	GLFDIAKKVIGVIGSL	Aurein2.6	16	LC₅₀=10-100 µM
1282	10951191	GLFDIVKKIAGHIAGSI	Aurein 3.1	17	LC₅₀ = 10 µM
1291	10951191	GLFDIVKKIAGHIASSI	Aurein 3.2	17	LC₅₀=10-100 µM
1300	10951191	GLFDIVKKIAGHIVSSI	Aurein 3.3	17	LC₅₀ = 10 µM
1428	16269280	KILRGVCKKIMRTFLRRISKDILTGKK	NK-2	27	LD₅₀=1-4 µM
1475	21252288	KWKSFAKTFKSAKKTVAHTALKAISS	L6A/L17A	26	IC₅₀=>83.6 µMo/L
1476	21252288	KWKSFLKTFKSAKKTVAHTAAKAISS	L17A/L21A	26	IC₅₀=>83.6 µMo/L
1477	21252288	KWKSFLKTFKSAKKTVAHTALKAISS	L17A	26	IC₅₀=>83.6 µMo/L
1478	21252288	KWKSFLKTFKSAKKTVAHTAAKAISS	L21A	26	IC₅₀=>83.6 µMo/L
1479	21252288	KWKSFAKTFKSAKKTVLHTALKAISS	L6A	26	IC₅₀=>83.6 µMo/L
1480	21252288	KWKSFLKTFKSAKKTVLHTALKAISS	P	26	IC₅₀=11.1 µMo/L
1481	21252288	KWKSFLKTFKSLKKTVLHTALKAISS	A12L	26	IC₅₀=6.4 µMo/L
1482	21252288	KWKSFLKTFKSAKKTVLHTLLKAISS	A20L	26	IC₅₀=5 µMo/L
1483	21252288	KWKSFLKTFKSLKKTVLHTLLKAISS	A12L/A20L	26	IC₅₀=4.3 µMo/L
1484	21252288	KWKSFLKTFKSLKKTVLHTLLKLISS	A12L/A20L/A23L	26	IC₅₀=3.5 µMo/L
1547	18656352	KAQIRAMECNIL	A5	12	Not Available
1548	18656352	RKKRRQRRR	Tat	9	~10% Cytotoxicity at 100 µM
1549	18656352	KAQIRAMECNILGRKKRRQRRR	Tat-a5	22	~80% Cytotoxicity at 100 µM
1634	12366526	PEWFKCRRWQWRMKKLGA	L1	18	IC₅₀=>404 µM
1635	12366526	PAWFKARRWAWRMKKLAA	L2	18	IC₅₀=>440 µM
1636	12366526	PAWRKAFRWAWRMKKLAA	L3	18	IC₅₀=141 µM
1637	12366526	PAWFKARRWAWRMLKKAA	L4	18	IC₅₀=57 µM
1638	12366526	PAWRKAFRWAWRMLKKAA	L5	18	IC₅₀=14 µM
1639	12366526	PAWRKAFRWAARMLKKAA	L6	18	IC₅₀=15 µM
1640	12366526	PAWRKAFRAAWRMLKKAA	L7	18	IC₅₀=16 µM
1641	12366526	PAWAKAFRAAARMKLKAA	L8	18	IC₅₀=180 µM
1642	12366526	PAWRKAARWAWRMLKKAA	L9	18	IC₅₀=52 µM
1643	12366526	PAARKAFRWAWRMLKKAA	L10	18	IC₅₀=35 µM
1644	12366526	PAARKAARWAWRMLKKGA	L11	18	IC₅₀=248 µM
1645	12366526	PAWRKAFRWAKRMLKKAA	L12	18	IC₅₀=25 µM
1646	12366526	PAWRKAFRKAWRMLKKAA	L13	18	IC₅₀=29 µM
1647	12366526	PAWRKARRWAWRMKKLAA	L14	18	IC₅₀=423 µM
1648	12366526	PAWRKARRWARRMKKLAA	L15	18	IC₅₀=178 µM
1669	15796184	LRVRLASHLRKLRKRLLRDADDLQKRLAVY	Apo E	30	65 % Cytotoxity at 40 µg/ml
1670	22641352	LLRHVVKILEKYL	Temporin-La	13	57.62 Inhibition ratio at 50 µg/ml
1671	22641352	LLRHVVKILSKYL	Temporin-Las	13	62.73 Inhibition ratio at 50 µg/ml
1672	22641352	RGDLLRHVVKILEKYL	RGD-La	16	72.69 Inhibition ratio at 50 µg/ml
1673	22641352	RGDLLRHVVKILSKYL	RGD-Las	16	81.465 Inhibition ratio at 50 µg/ml
1734	None	FLGWLFKWAKK	Gaegurin peptides SEQID NO: 1	11	IC₅₀ = 27 mM
1735	None	FLKWLFKWAKK	Gaegurin peptides SEQID NO: 2	11	IC₅₀ = 14.8 mM
1736	None	FLGWLFKWAWK	Gaegurin peptides SEQID NO: 3	11	IC₅₀ = 24.63 mM
1737	None	FLWWLFKWAWK	Gaegurin peptides SEQID NO: 4	11	IC₅₀ = 14.8 mM
1738	None	FLGWLFKWAKK	Gaegurin peptides SEQID NO: 1	11	Not Available
1739	None	FLKWLFKWAKK	Gaegurin peptides SEQID NO: 2	11	Not Available
1740	None	FLGWLFKWAWK	Gaegurin peptides SEQID NO: 3	11	IC₅₀ = 48 mM
1741	None	FLWWLFKWAWK	Gaegurin peptides SEQID NO: 4	11	IC₅₀ = 57 mM
1745	None	FLGWLFKWAKK	Gaegurin peptides SEQID NO: 1	11	Not Available
1751	None	FLKWLFKWAKK	Gaegurin peptides SEQID NO: 2	11	IC₅₀ = 14.8 mM
1753	None	FLKWLFKWAKK	Gaegurin peptides SEQID NO: 2	11	Not Available
1759	None	FLGWLFKWAWK	Gaegurin peptides SEQID NO: 3	11	IC₅₀ = 24.63 mM
1761	None	FLGWLFKWAWK	Gaegurin peptides SEQID NO: 3	11	IC₅₀ = 48 mM
1767	None	FLWWLFKWAWK	Gaegurin peptides SEQID NO: 4	11	IC₅₀ = 14.8 mM
1769	None	FLWWLFKWAWK	Gaegurin peptides SEQID NO: 4	11	IC₅₀ = 57 mM
1925	None	FALALKALKKALKKLKKALKKAL	Hecate AC	23	LD₅₀ =6 µg/ml
1926	None	FALALKALKKALKKLKKALKKAL	Hecate AM	23	LD₅₀ =46 µg/ml
1927	None	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	SB-37 AC	38	LD₅₀ =82 µg/ml
1928	None	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	SB-37 AM	38	LD₅₀ =>1000 µg/ml
1929	None	FAKKLAKKLKKLAKKLAKLALAL	SHIVA 10 AC	23	Not Available
1930	None	FALAAKALKKLAKKLKKLAKKAL	FLAK01 AM	23	LD₅₀ =5 µg/ml
1931	None	FALALKALKKLLKKLKKLAKKAL	FLAK03 AM	23	LD₅₀ =38 µg/ml
1932	None	FALALKALKKLAKKLKKLAKKAL	FLAK04 AM	23	LD₅₀ =12 µg/ml
1933	None	FALAKLAKKAKAKLKKALKAL	FLAK05 AM	21	LD₅₀ =8 µg/ml
1934	None	FALALKALKKLKKALKKAL	FLAK06 AM	19	LD₅₀ =26 µg/ml
1935	None	FALALKALKKLKKALKKAL	FLAK06 AC	19	LD₅₀ =59 µg/ml
1936	None	FAKKLAKKLKKLAKLALAL	FLAK06 R-AC	19	LD₅₀ =210 µg/ml
1937	None	VALALKALKKALKKLKKALKKAL	KAL V	23	LD₅₀ =62 µg/ml
1938	None	FALALKKALKALKKAL	FLAK 17 AM	16	LD₅₀ =35 µg/ml
1939	None	FAKKLAKLAKKLAKLAL	FLAK 26 AM	17	LD₅₀ =14 µg/ml
1940	None	FAKKLAKLAKKLAKLALAL	FLAK 25 AM	19	LD₅₀ =30 µg/ml
1941	None	FALALKALKKALkkLKKALKKAL	HECATE 2DAc	23	LD₅₀ =57 µg/ml
1942	None	FAKKLAKLAKKLLAL	FLAK43 AM	15	LD₅₀ =13 µg/ml
1943	None	FAKKLAKLAKKALAL	FLAK44 AM	15	LD₅₀ =435 µg/ml
1944	None	FALAKKALKKAKKAL	FLAK62 AM	15	LD₅₀ =>1000 µg/ml
1945	None	FAKKLAKKLKKLAKLALAK	FLAK 06R-AM	19	LD₅₀ =120 µg/ml
1946	None	GIGKFLKKAKKFGKAFVKILKK	MSI-78 AM	22	LD₅₀ =34 µg/ml
1947	None	FAKLLAKLAKKLL	FLAK50	13	LD₅₀ =9 µg/ml
1948	None	FAKKLAKLALKLAKL	FLAK51	15	LD₅₀ =32 µg/ml
1949	None	FAKKLAKKLAKLAL	FLAK57	14	LD₅₀ =180 µg/ml
1950	None	FAKKLKKLAKLAKKL	FLAK71	15	LD₅₀ =160 µg/ml
1951	None	FAKKALKALKKL	FLAK77	12	LD₅₀ =>1000 µg/ml
1952	None	VAKLLAKLAKKLL	FLAK50V	13	LD₅₀ =47 µg/ml
1953	None	FAKLLAKLAKKL	FLAK50F	12	LD₅₀ =100 µg/ml
1954	None	VAKKLAKLAKKLAKLAL	FLAK26V AM	17	LD₅₀ =46 µg/ml
1955	None	KWKLFKKIGAVLKVL	CAME-15	15	Not Available
1956	None	FAKLLAKLAKKAL	FLAK50C	13	Not Available
1957	None	FAKLLAKALKKLL	FLAK50D	13	LD₅₀ =14 µg/ml
1958	None	FAKLLKLAAKKLL	FLAK 50E	13	LD₅₀ =215 µg/ml
1959	None	FAKLLAKKLL	FLAK80	10	LD₅₀ =740 µg/ml
1960	None	FAKKLAKALL	FLAK81	10	LD₅₀ =>1000 µg/ml
1961	None	FAKKLAKKLL	FLAK82	10	LD₅₀ =42 µg/ml
1962	None	FAKLAKKLL	FLAK83M	9	LD₅₀ =>1000 µg/ml
1963	None	FAKKLAKLAKKLAKLAL	FLAK 26 Ac	17	LD₅₀ =100 µg/ml
1964	None	ILPWKWPWWPWRR	Indolicidin	13	LD₅₀ =345 µg/ml
1965	None	FAKALKALLKALKAL	FLAK 17 C	15	LD₅₀ = µg/ml
1966	None	FAKLLAKLAKAKL	FLAK 50H	13	LD₅₀ =345 µg/ml
1967	None	FAKLLAKLAKLKL	FLAK 50G	13	LD₅₀ =145 µg/ml
1968	None	FAKKLAKKLKKLAKKLAKKWKL	SHIVA DERIV P69 + KWKL	22	LD₅₀ =11 µg/ml
1969	None	FAKKLAKKLKKLAKKLAK	Shiva 10(1-18 AC)	18	LD₅₀ =250 µg/ml
1970	None	FAKKLAKKLKKLAKKLAKKWKL	SHIVA 10 PEPTIDE 71 + KWKL	22	LD₅₀ =82 µg/ml
1971	None	KWKLFKKKTKLFKKFAKKLAKKL	CA(1-7) Shiva10(1-16)	23	LD₅₀ =70 µg/ml
1972	None	FAKKLAKKLAKAL	FLAK 54	13	LD₅₀ =340 µg/ml
1973	None	FAKKLAKKLAKLL	FLAK 56	13	LD₅₀ =17 µg/ml
1974	None	FAKKLAKKLAKAAL	FLAK 58	14	LD₅₀ =400 µg/ml
1975	None	FAKKLAKKAKLAKKL	FLAK 72	15	LD₅₀ =>1000 µg/ml
1976	None	FAKKLKKLAKKL	FLAK 75	12	LD₅₀ =>1000 µg/ml
1977	None	KTKLFKKFAKKLAKKLKKLAKKL	SHIVA 10 (1-16) Ac	23	LD₅₀ =35 µg/ml
1978	None	KWKLFKKKTKLFKKFAKKLAKKL	CA(1-7) Shiva10(1-16)-COOH	23	LD₅₀ =13 µg/ml
1979	None	ILPWKWPWWPWRR	Indolocidin-ac	13	LD₅₀ =30 µg/ml
1980	None	FAKALAKLAKKLL	FLAK50B	13	LD₅₀ =51 µg/ml
1981	None	FAKLLALALKLKL	FLAK50I	13	Not Available
1982	None	FAKLLAKLAKAKA	FLAK50K	13	LD₅₀ =>1000 µg/ml
1983	None	FAKLLAKLAKAKG	FLAK50L	13	LD₅₀ =>1000 µg/ml
1984	None	FAKKLAKKLKKLAKKLAKLALALKALALKAL	Shiva-11	31	LD₅₀ =125 µg/ml
1985	None	FAKKLAKKLKKLAKKLIGAVLKV	SHIVA 11[(1-16)ME(2-9]-COOH	23	LD₅₀ =120 µg/ml
1986	None	FAKLLAKALKLKL	FLAK 50N	13	LD₅₀ =170 µg/ml
1987	None	FAKLLAKALKKAL	FLAK 50O	13	LD₅₀ =57 µg/ml
1988	None	FAKLLAKALKKL	FLAK 50P	12	LD₅₀ =90 µg/ml
1989	None	KWKLFKKALKKLKKALKKAL	CA(1-& HECATE(11/23)	20	LD₅₀ =54 µg/ml
1990	None	KIAKVALAKLGIGAVLKVLTTGL	PYL-ME	23	LD₅₀ =>1000 µg/ml
1991	None	FAKKLAKLAKKL	FLAG26-D1	12	LD₅₀ =570 µg/ml
1992	None	MPKEKVFLKIEKMGRNIRN	VISHNU3	19	LD₅₀ =>1000 µg/ml
1993	None	GIGAVLKVLTTGLPALISWIKRKRQQ	MELITTIIN	26	LD₅₀ =23 µg/ml
1994	None	FAKKLAKLAKKLAKAL	FLAK26-D2	16	LD₅₀ =>1000 µg/ml
1995	None	FAKKLLAKALKL	FLAG26-D3	12	LD₅₀ =325 µg/ml
1996	None	FAKFLAKFLKKAL	FLAK50 Q1	13	LD₅₀ =27 µg/ml
1997	None	FAKLLFKALKKAL	FLAK50 Q2	13	LD₅₀ =800 µg/ml
1998	None	FAKLLAKFLKKAL	FLAK50 Q3	13	LD₅₀ =180 µg/ml
1999	None	FAKLLAKAFKKAL	FLAK50 Q4	13	LD₅₀ =>1000 µg/ml
2000	None	FAKLFAKAFKKAL	FLAK50 Q5	13	LD₅₀ =>1000 µg/ml
2001	None	FAKLLAKALKKFL	FLAK50 Q6	13	LD₅₀ =115 µg/ml
2002	None	FAKLLAKALKKFAL	FLAK50 Q7	14	LD₅₀ =46 µg/ml
2003	None	FAKLLAKLAKKFAL	FLAK50 Q8	14	LD₅₀ =630 µg/ml
2004	None	FAKLFAKLAKKFAL	FLAK50 Q9	14	LD₅₀ =800 µg/ml
2005	None	FKLAFKLAKKAFL	FLAK50 Q10	13	LD₅₀ =570 µg/ml
2006	None	FAKLLAKLAK	FLAK50 T1	10	LD₅₀ =>1000 µg/ml
2007	None	FAKLLAKLAKKVL	FLAK50 T2	13	LD₅₀ =9 µg/ml
2008	None	FAKLLAKLAKKIL	FLAK50 T3	13	LD₅₀ =125 µg/ml
2009	None	FAKLLAKLAKKEL	FLAK50 T4	13	LD₅₀ =>1000 µg/ml
2010	None	FAKLLAKLAKKSL	FLAK50 T5	13	LD₅₀ =400 µg/ml
2011	None	FAKLA	FLAK90	5	LD₅₀ =530 µg/ml
2012	None	FAKLF	FLAK91	5	LD₅₀ =550 µg/ml
2013	None	KAKLF	FLAK92	5	LD₅₀ =>1000 µg/ml
2014	None	KWKLF	FLAK93	5	LD₅₀ =555 µg/ml
2015	None	FGKGIGKVGKKLL	FLAK50 Z1	13	LD₅₀ =>1000 µg/ml
2016	None	FAFGKGIGKVGKKLL	FLAK50 Z2	15	LD₅₀ =>1000 µg/ml
2017	None	FAKAIAKIAFGKGIGKVGKKLL	FLAK50 Z3	22	LD₅₀ =740 µg/ml
2018	None	FAKLWAKLAFGKGIGKVGKKLL	FLAK50 Z4	22	LD₅₀ =80 µg/ml
2019	None	FAKLWAKLAKKL	FLAK50 Z5	12	LD₅₀ =600 µg/ml
2020	None	FAKGVGKVGKKAL	FLAK50 Z6	13	LD₅₀ =>1000 µg/ml
2021	None	FAFGKGIGKIGKKGL	FLAK50 Z7	15	LD₅₀ =>1000 µg/ml
2022	None	FAKIIAKIAKIAKKIL	FLAK50 Z8	16	LD₅₀ =>1000 µg/ml
2023	None	FAFAKIIAKIAKKII	FLAK50 Z9	15	LD₅₀ =>1000 µg/ml
2024	None	FALALKA	FLAK94	7	LD₅₀ =560 µg/ml
2025	None	KWKLAKKALALL	FLAK93B	12	LD₅₀ =38 µg/ml
2026	None	FAKIIAKIAKKI	FLAK50 Z10	12	LD₅₀ =>1000 µg/ml
2027	None	FALALKALKKAL	FLAK96	12	LD₅₀ =285 µg/ml
2028	None	FALKALKK	FLAK97	8	LD₅₀ =>1000 µg/ml
2029	None	KYKKALKKLAKLL	FLAK98	13	LD₅₀ =380 µg/ml
2030	None	FKRLAKIKVLRLAKIKR	FKRLA	17	LD₅₀ =185 µg/ml
2031	None	FAKLAKKALAKLL	FLAK91B	13	LD₅₀ =>1000 µg/ml
2032	None	KAKLAKKALAKLL	FLAK92B	13	LD₅₀ =>1000 µg/ml
2033	None	KLALKLALKALKAAKLA	FLAK99	17	LD₅₀ =235 µg/ml
2034	None	FAKLLAKLAKK	FLAK50T6	11	LD₅₀ =>1000 µg/ml
2035	None	FAKLLAKLAKKGL	FLAK50T7	13	LD₅₀ =740 µg/ml
2036	None	FALKALKKLKKALKKAL	FLAK95	17	LD₅₀ =61 µg/ml
2037	None	VAKLLAKLAKKVL	FLAK50T8	13	LD₅₀ =750 µg/ml
2038	None	YAKLLAKLAKKAL	FLAK50T9	13	LD₅₀ =>1000 µg/ml
2039	None	KLLKLLLKLYKKLLKLL	FLAK100-CO2H	17	LD₅₀ =345 µg/ml
2040	None	FAVGLRAIKRALKKLRRGVRKVAKDL	FAGVL	26	LD₅₀ =530 µg/ml
2041	None	KLAKKLAKLAKLAKAL	Modelin-5	16	LD₅₀ =140 µg/ml
2042	None	KLAKKLAKLAKLAKAL	Modelin-5-CO2H	16	LD₅₀ =370 µg/ml
2043	None	KWKKLAKKW	FLAK120	9	LD₅₀ =240 µg/ml
2044	None	FALAKALKKAL	FLAK121	11	LD₅₀ =>1000 µg/ml
2045	None	FALALKLAKKAL	FLAK96B	12	LD₅₀ =360 µg/ml
2046	None	FALLKL	FLAK96G	6	LD₅₀ =>1000 µg/ml
2047	None	FALALKALKK	FLAK96F	10	LD₅₀ =>1000 µg/ml
2048	None	FALKALKKAL	FLAK96C	10	LD₅₀ =>1000 µg/ml
2049	None	FALLKALKKAL	FLAK96D	11	LD₅₀ =770 µg/ml
2050	None	KFKKLAKKF	Modelin-8D	9	LD₅₀ =>1000 µg/ml
2051	None	KFKKLAKKW	Modelin-8E	9	LD₅₀ =70 µg/ml
2052	None	FALALKALKKA	Flak 96H	11	LD₅₀ =>1000 µg/ml
2053	None	FALLKALLKKAL	Flak 96I	12	LD₅₀ =310 µg/ml
2054	None	FALALKLAKKL	Flak 96J	11	LD₅₀ =>1000 µg/ml
2055	None	LKKLAKLALAF	Flak 96L	11	LD₅₀ =>1000 µg/ml
2056	None	VALALKALKKL	FLAK-120G	11	LD₅₀ =600 µg/ml
2057	None	FALALKLKKL	FLAK-120D	10	LD₅₀ =870 µg/ml
2058	None	FALALKAKKL	FLAK-120C	10	LD₅₀ =>1000 µg/ml
2059	None	FALA	FLAK-120B	4	LD₅₀ =>1000 µg/ml
2060	None	WALAL	FLAK-120F	5	LD₅₀ =440 µg/ml
2061	None	GIGKFLHAAKKFAKAFVAEIMNS	Magainin2wisc	23	LD₅₀ =60 µg/ml
2062	None	FAKKFAKKFKKFAKKFAKFAFAF	D2A21	23	LD₅₀ =76 µg/ml
2063	None	KKVVFKVKFK	KSL-1	10	LD₅₀ =>1000 µg/ml
2064	None	FKVKFKVKVK	KSL-7	10	LD₅₀ =530 µg/ml
2065	None	LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	LSB-37	38	LD₅₀ =240 µg/ml
2066	None	FAKKLAKKLKKLAKKLAKLAKKL	Anubis-2	23	LD₅₀ =73 µg/ml
2067	None	FAKKLAKLAKKLAKLALAL	FLAK 17 CV	19	Not Available
2068	None	VAKFLAKFLKKAL	FLAK50 Q1V	13	Not Available
2069	None	VAKKFAKKFKKFAKKFAKFAFAF	D2A21V	23	Not Available
2070	None	FAKKLAKLAKKLAKLALAL	FLAK 25 AM V	19	Not Available
2071	None	FAKKLAKLAKKLLAL	FLAK43 AM V	15	Not Available
2072	None	VAKLLAKALKKLL	FLAK50D V	13	Not Available
2073	None	VALALKALKKALKKLKKALKKAL	Hecate AM V	23	Not Available
2074	None	VALALKALKKALKKLKKALKKAL	Hecate AC V	23	Not Available
2075	None	FALALKALKKLAKKLKKLAKKAL	FLAK04 AM V	23	Not Available
2076	None	FAKLLAKLAKKAA	FLAK50J	13	Not Available
3102	22783018	PDEDAINNALNKVCSTGRRQRSICKQLLKK	N29N	30	100% cell viability at 5 µM
3103	22783018	PDEDAINNALNKVCSTGRRQRSICKQLLKK	N29N	30	40% cell viability at 50 µM
3108	22783018	PDEDAINDALNKVCSTGRRQRSICKQLLKK	N29D	30	>100% cell viability at 5 µM
3109	22783018	PDEDAINDALNKVCSTGRRQRSICKQLLKK	N29D	30	60% cell viability at 50 µM
3159	23301519	WRWRWRWRW	Cyclic [W(RW)4 ]-Dox	9	50-67% inhibition of cell proliferation at 1 µM
3163	23301519	RWRWRWRW	linear (RW)4-Dox	8	21-61% antiproliferative activity at 1 µM
3175	17559067	fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL	Peptide 5	40	16.5 % inhibition of cell proliferation at 1 nM
3176	17559067	fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL	Peptide 5	40	14.2 % inhibition of cell proliferation at 10 nM
3177	17559067	fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL	Peptide 5	40	16.8 % inhibition of cell proliferation at 100 nM
3178	17559067	fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL	Peptide 5	40	21.7 % inhibition of cell proliferation at 1 µM
3179	17559067	fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL	Peptide 5	40	27.9 % inhibition of cell proliferation at 10 µM
3187	17559067	fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL	Peptide 5	40	ED₅₀ >10 µM
3228	22644847	FLGWLFKWAWK	GA-W3	11	IC₅₀ =24.63 µM
3235	22644847	FLWWLFKWAWK	GA-W4	11	IC₅₀ =14.80 µM
3242	22644847	FLGWLFKWAKK	GA-K3	11	IC₅₀ =27.00 µM
3249	22644847	FLKWLFKWAKK	GA-K4	11	IC₅₀ =14.80 µM
3254	22783018	PDEDAINNALNKVCSTGRRQRSICKQLLKK	N29N	30	100% cell viability at 5 µM
3255	22783018	PDEDAINNALNKVCSTGRRQRSICKQLLKK	N29N	30	40% cell viability at 50 µM
3260	22783018	PDEDAINDALNKVCSTGRRQRSICKQLLKK	N29D	30	>100% cell viability at 5 µM
3261	22783018	PDEDAINDALNKVCSTGRRQRSICKQLLKK	N29D	30	60% cell viability at 50 µM
3281	19527490, 23533710	FKCRRWQWRMKK	LfcinB	12	IC₅₀ =148±8 µM
3289	19527490	KAAKKAAKAAKKAAKAAKKAA	KW5	21	IC₅₀ =55±14 µM
3305	21453492	WKKW-Dip-KKWK	LTX-302	9	IC₅₀ =75 ± 5 µM
3308	21453492	KKWWKKW-Dip-K	LTX-315	9	IC₅₀ =38 ± 3 µM
3311	21453492	OOW-Dip-OOWWO	LTX-318	9	IC₅₀ =248 ± 5 µM
3314	21453492, 23533710	FKCRRWQWRMKK	LfcinB	12	IC₅₀ > 160 µM
3341	23533710	FKCRRWQWRMKK	LfcinB	12	Inhibition at 0.1g/l
3342	23533710	YPFPG	β-Casomorphins 5 f(60_64)	4	Inhibition at 9-11g/l
3343	23533710	RYLGYL	αs1-casein f(90_95)	6	Inhibition at 12-15g/l
3344	23533710	PPPEE	Caseinphosphopeptides	5	Inhibition at 24-28g/l
3362	None	NHFTLKCPKTALTEPPTLAY	TG20	20	<5% cytotoxicity at 1 µM
3363	None	NHFTLKCPKTALTEPPTLAY	TG20	20	<20% cytotoxicity at 10 µM
3364	None	NHFTLKCPKTALTEPPTLAY	TG20	20	~15% cytotoxicity at 1 µM
3365	None	NHFTLKCPKTALTEPPTLAY	TG20	20	>20% cytotoxicity at 10 µM
3366	None	NHFTLKCPKTALTEPPTLAY	TG20	20	<5% cytotoxicity at 1 µM
3367	None	NHFTLKCPKTALTEPPTLAY	TG20	20	<5% cytotoxicity at 10 µM
3368	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	<5% cytotoxicity at 1 µM
3369	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	~10% cytotoxicity at 10 µM
3370	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	10% cytotoxicity at 1 µM
3371	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	>10% cytotoxicity at 10 µM
3372	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	>10% cytotoxicity at 1 µM
3373	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	<5% cytotoxicity at 10 µM
3374	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	<5% cytotoxicity at 1 µM
3375	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	<5% cytotoxicity at 10 µM
3376	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	>20% cytotoxicity at 1 µM
3377	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	~35% cytotoxicity at 10 µM
3378	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	<5% cytotoxicity at 1 µM
3379	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	~20% cytotoxicity at 10 µM
3398	None	NHFTLKCPKTALTEPPTLAY	TG20	20	20% cytotoxicity at 1 µM
3399	None	NHFTLKCPKTALTEPPTLAY	TG20	20	10% cytotoxicity at 10 µM
3400	None	NHFTLKCPKTALTEPPTLAY	TG20	20	<5% cytotoxicity at 1 µM
3401	None	NHFTLKCPKTALTEPPTLAY	TG20	20	<3% cytotoxicity at 10 µM
3402	None	NHFTLKCPKTALTEPPTLAY	TG20	20	<20% cytotoxicity at 1 µM
3403	None	NHFTLKCPKTALTEPPTLAY	TG20	20	15% cytotoxicity at 10 µM
3404	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	<15% cytotoxicity at 1 µM
3405	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	15% cytotoxicity at 10 µM
3406	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	~5% cytotoxicity at 1 µM
3407	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	<5% cytotoxicity at 10 µM
3408	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	<5% cytotoxicity at 1 µM
3409	None	TAGIKLTVPIEKFPVTTQTFWG	TG23	22	<5% cytotoxicity at 10 µM
3410	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	>40% cytotoxicity at 1 µM
3411	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	50% cytotoxicity at 10 µM
3412	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	<20% cytotoxicity at 1 µM
3413	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	>20% cytotoxicity at 10 µM
3414	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	>30% cytotoxicity at 1 µM
3415	None	GQVWEATATVNAIRGSVTPAVSQFNARTAD	MB30	30	~40% cytotoxicity at 10 µM
3519	22100226	VNWKKILGKIIKVVK	LL-III/37	15	IC₅₀ = 5±1 µM
3520	22100226	VNWKKILGKIIKVVK	LL-III	15	IC₅₀ = 18±4 µM
3521	22100226	VNWKKILAKIIKVVK	LL-III/1	15	IC₅₀ = 12± 3 µM
3522	22100226	NVWKKILGKIIKVVK	LL-III/2	15	IC₅₀ = 11 µM
3523	22100226	VNWKKILKKIIKVVK	LL-III/3	15	IC₅₀ > 40 µM
3524	22100226	VNWKKILGKIKKVVK	LL-III/4	15	IC₅₀ > 40 µM
3525	22100226	VNWKKILPKIIKVVK	LL-III/6	15	Not tested
3526	22100226	VNWKKILGKIIKVVK	LL-III/8	15	Not tested
3527	22100226	VNWKKILGKIIKVVK	LL-III/9	15	IC₅₀ = 25± 5 µM
3528	22100226	KNWKKILGKIIKVVK	LL-III/10	15	Not tested
3529	22100226	VNWKKIILGKIIKVVK	LL-III/11	15	IC₅₀ = 48 µM
3530	22100226	vnwkkilgkiikvvk	LL-III/12	15	IC₅₀ = 20 µM
3531	22100226	VNFKKLLGKLLKVVK	LL-III/15	15	IC₅₀ = 42 µM
3532	22100226	VN-Nal-KKLLGKLLKVVK	LL-III/16	15	Not tested
3533	22100226	VNWRRILGRIIRVVR	LL-III/17	15	Not tested
3534	22100226	KNWKKILKKIIKVVK	LL-III/18	15	Not tested
3535	22100226	VNWKK-Aib-LGK-Aib-IK-Aib-VK	LL-III/19	15	IC₅₀ = 28 µM
3536	22100226	KNWKK-Aib-LKK-Aib-IK-Aib-VK	LL-III/22	15	IC₅₀ > 100 µM
3537	22100226	VNWKKLLGKLLKVVK	LL-III/23	15	IC₅₀ = 15 µM
3538	22100226	VNWOOILGOIIOVVO	LL-III/24	15	IC₅₀ = 20 µM
3539	22100226	vnwkkllgkllkvvk	LL-III/25	15	IC₅₀ = 20 µM
3540	22100226	VYWKKILGKIIKVVK	LL-III/26	15	IC₅₀ = 30 µM
3541	22100226	VNWKKVLGKVVKVVK	LL-III/27	15	IC₅₀ > 100 µM
3542	22100226	NKWKKILGKIIKVVK	LL-III/34	15	IC₅₀ = 37 µM
3543	22100226	VNWKKILAKIIKVVK	LL-III/36	15	Not tested
3544	22100226	VNWKKILGKIIKVVK	LL-III/37	15	IC₅₀ = 13 µM
3602	22100226	GFGMALKLLKKVL	MAC1	13	IC₅₀ = 23±4 µM
3603	22100226	GTGLPMSERRKIMLMMR	MAC2	17	IC₅₀ > 100 µM
3604	22100226	gfgmalkllkkvl	MAC1/1	13	IC₅₀ = 19±2 µM
3605	22100226	AFGMALKLLKKVL	MAC1/2	13	IC₅₀ = 16 µM
3606	22100226	LFGMALKLLKKVL	MAC1/3	13	IC₅₀ = 11±1 µM
3607	22100226	GFGMALKLLKKVL	MAC1/4	13	IC₅₀ = 49±9 µM
3608	22100226	GFGMALKLLKKVL	MAC1/6	13	IC₅₀ = 29±3 µM
3609	22100226	GFKMALKLLKKVL	MAC1/9	13	IC₅₀ = 13±3 µM
3610	22100226	GFKMALKLLKKVL	MAC1/10	13	Not tested
3611	22100226	GFGMALKLLKKVL	MAC1/16	13	IC₅₀ > 100 µM
3612	22100226	GFGMALKLLKKVL	MAC1/19	13	IC₅₀ = 68±2 µM
3613	22100226	GFGMALOLLOOVL	MAC1/20	13	IC₅₀ = 35±4 µM
3614	22100226	GFGMALRLLRRVL	MAC1/21	13	IC₅₀ = 17±2 µM
3615	22100226	GFGMALKL-(AC6C)-KKVL	MAC1/24	13	IC₅₀ = 16±1 µM
3616	22100226	GFGMALK-(AC6C)-LKKVL	MAC1/25	13	IC₅₀ = 14±1 µM
3617	22100226	GFGMA-(AC6C)-KLLKKVL	MAC1/26	13	IC₅₀ = 18±1 µM
3662	22100226	GMWSKILGHLIR	HAL-1	12	IC₅₀ = 44±8 µM
3663	22100226	gmwskilghlir	HAL-1/22	12	IC₅₀ > 40 µM
3664	22100226	GMWSKILGHLIK	HAL-1/6	12	IC₅₀ > 100 µM
3665	22100226	GMWSKILGHLKR	HAL-1/4	12	Not tested
3666	22100226	GMWSKILGKLIR	HAL-1/9	12	IC₅₀ > 50 µM
3667	22100226	GMWSKILKHLIR	HAL-1/18	12	IC₅₀ = 18±2 µM
3668	22100226	GMWKKILGHLIR	HAL-1/5	12	IC₅₀ = 44±5 µM
3669	22100226	GKWSKILGHLIR	HAL-1/12	12	IC₅₀ > 100 µM
3670	22100226	KMWSKILGHLIR	HAL-1/17	12	IC₅₀ > 100 µM
3671	22100226	GMWKKILGKLIR	HAL-1/10	12	IC₅₀ > 60 µM
3672	22100226	GKWSKILGKLIR	HAL-1/20	12	IC₅₀ > 40 µM
3673	22100226	GKWKKILGHLIR	HAL-1/19	12	IC₅₀ > 100 µM
3674	22100226	GKWKKILGKLIR	HAL-1/21	12	IC₅₀ > 100 µM
3675	22100226	GMWSKILGHLIR	HAL-1/29	12	Not tested
3676	22100226	GMWSKLLGHLLR	HAL-1/15	12	IC₅₀ > 40 µM
3677	22100226	GKWMSLLKHILK	HAL-2	12	IC₅₀ = 35±3 µM
3678	22100226	gkwmsllkhilk	HAL-2/22	12	IC₅₀ > 100 µM
3679	22100226	GKWMSLLKKILK	HAL-2/4	12	IC₅₀ = 38±6 µM
3680	22100226	GKWMKLLKHILK	HAL-2/2	12	IC₅₀ = 35±5 µM
3681	22100226	GKWKSLLKHILK	HAL-2/1	12	IC₅₀ > 100 µM
3682	22100226	GKWMSLLKHILK	HAL-2/8	12	IC₅₀ > 40 µM
3683	22100226	GKWMSLLKHIWK	HAL-2/18	12	IC₅₀ > 40 µM
3684	22100226	GKWMSLLKHWLK	HAL-2/19	12	IC₅₀ > 40 µM
3685	22100226	GKWMSLWKHILK	HAL-2/20	12	IC₅₀ > 40 µM
3686	22100226	GKFMSLLKHILK	HAL-2/24	12	IC₅₀ > 40 µM
3687	22100226	GKWMSFLKHILK	HAL-2/6	12	IC₅₀ > 40 µM
3688	22100226	GKWMTLLKHILK	HAL-2/13	12	IC₅₀ > 60 µM
3689	22100226	GKWLSLLKHILK	HAL-2/11	12	IC₅₀ = 40 µM
3724	9815815	fAYwKAT	Lan-7	7	IC₅₀= 29.97±1.19 µM
3729	22644847	FLGWLFKWAWK	GA-W3	11	IC₅₀= 24.63 µM
3736	22644847	FLWWLFKWAWK	GA-W4	11	IC₅₀= 14.80 µM
3743	22644847	FLGWLFKWAKK	GA-K3	11	IC₅₀= 27.00 µM
3750	22644847	FLKWLFKWAKK	GA-K4	11	IC₅₀= 14.8 µM
3858	16722632	YA*	8	2	9.8% inhibition at 10^-6
3859	16722632	YA*	8	2	1.6% inhibition at 10^-5
3860	16722632	YA*	8	2	5.4% inhibition at 10^-4
3861	16722632	YA*	8	2	26.5% inhibition at 10^-3
3862	16722632	YA*	8	2	12.9% inhibition at 10^-6
3863	16722632	YA*	8	2	16.5% inhibition at 10^-5
3864	16722632	YA*	8	2	28.1% inhibition at 10^-4
3865	16722632	YA*	8	2	58.2% inhibition at 10^-3
3866	16722632	YA*	8	2	3.5% inhibition at 10^-6
3867	16722632	YA*	8	2	22.7% inhibition at 10^-5
3868	16722632	YA*	8	2	18.9% inhibition at 10^-4
3869	16722632	YA*	8	2	26.4% inhibition at 10^-3
3882	16722632	YSA*	9	3	4.9% inhibition at 10^-6
3883	16722632	YSA*	9	3	8.9% inhibition at 10^-5
3884	16722632	YSA*	9	3	3.4% inhibition at 10^-4
3885	16722632	YSA*	9	3	20.8% inhibition at 10^-3
3886	16722632	YSA*	9	3	10.5% inhibition at 10^-6
3887	16722632	YSA*	9	3	21.9% inhibition at 10^-5
3888	16722632	YSA*	9	3	11.8% inhibition at 10^-4
3889	16722632	YSA*	9	3	17.9% inhibition at 10^-3
3890	16722632	YSA*	9	3	3.7% inhibition at 10^-6
3891	16722632	YSA*	9	3	16.5% inhibition at 10^-5
3892	16722632	YSA*	9	3	8.4% inhibition at 10^-4
3893	16722632	YSA*	9	3	14.5% inhibition at 10^-3
3909	16722632	YSA*	10	3	0.7% inhibition at 10^-6
3910	16722632	YSA*	10	3	8.3% inhibition at 10^-5
3911	16722632	YSA*	10	3	10.5% inhibition at 10^-4
3912	16722632	YSA*	10	3	21.8% inhibition at 10^-3
3913	16722632	YSA*	10	3	10.7% inhibition at 10^-6
3914	16722632	YSA*	10	3	10.0% inhibition at 10^-5
3929	16722632	YSA*G	15	4	5.4% inhibition at 10^-6M
3930	16722632	YSA*G	15	4	7.4% inhibition at 10^-5M
3931	16722632	YSA*G	15	4	9.5% inhibition at 10^-4M
3932	16722632	YSA*G	15	4	15.7% inhibition at 10^-3M
3933	16722632	YSA*G	15	4	13.6% inhibition at 10^-6M
3934	16722632	YSA*G	15	4	20.4% inhibition at 10^-5M
3935	16722632	YSA*G	15	4	14.4% inhibition at 10^-4M
3936	16722632	YSA*G	15	4	23.4% inhibition at 10^-3M
3937	16722632	YSA*G	15	4	2.2% inhibition at 10^-6M
3938	16722632	YSA*G	15	4	4.2% inhibition at 10^-5M
3939	16722632	YSA*G	15	4	6.4% inhibition at 10^-4M
3940	16722632	YSA*G	15	4	6.2% inhibition at 10^-3M
3953	16722632	YRA*G	16	4	7.6% inhibition at 10^-6M
3954	16722632	YRA*G	16	4	3.8% inhibition at 10^-5M
3955	16722632	YRA*G	16	4	12.4% inhibition at 10^-4M
3956	16722632	YRA*G	16	4	22.4% inhibition at 10^-3M
3957	16722632	YRA*G	16	4	17.0% inhibition at 10^-6M
3958	16722632	YRA*G	16	4	13.5% inhibition at 10^-5M
3959	16722632	YRA*G	16	4	13.5% inhibition at 10^-4M
3960	16722632	YRA*G	16	4	25.3% inhibition at 10^-3M
3961	16722632	YRA*G	16	4	8.1% inhibition at 10^-6M
3962	16722632	YRA*G	16	4	6.9% inhibition at 10^-5M
3963	16722632	YRA*G	16	4	8.1% inhibition at 10^-4M
3964	16722632	YRA*G	16	4	8.6% inhibition at 10^-3M
3978	16722632	YA*GFM	17	5	3.3% inhibition at 10^-6M
3979	16722632	YA*GFM	17	5	11.0% inhibition at 10^-5M
3980	16722632	YA*GFM	17	5	7.9% inhibition at 10^-4M
3981	16722632	YA*GFM	17	5	23.7% inhibition at 10^-3M
3982	16722632	YA*GFM	17	5	12.2% inhibition at 10^-6M
3983	16722632	YA*GFM	17	5	15.5% inhibition at 10^-5M
3984	16722632	YA*GFM	17	5	24.7% inhibition at 10^-4M
3985	16722632	YA*GFM	17	5	29.0% inhibition at 10^-3M
3986	16722632	YA*GFM	17	5	3.0% inhibition at 10^-6M
3987	16722632	YA*GFM	17	5	8.4% inhibition at 10^-5M
3988	16722632	YA*GFM	17	5	18.5% inhibition at 10^-4M
3989	16722632	YA*GFM	17	5	10.6% inhibition at 10^-3M
4003	16722632	YA*GFM	18	5	16.2% inhibition at 10^-6M
4004	16722632	YA*GFM	18	5	6.6% inhibition at 10^-5M
4005	16722632	YA*GFM	18	5	5.1% inhibition at 10^-4M
4006	16722632	YA*GFM	18	5	14.5% inhibition at 10^-3M
4007	16722632	YA*GFM	18	5	26.4% inhibition at 10^-6M
4008	16722632	YA*GFM	18	5	13.1% inhibition at 10^-5M
4009	16722632	YA*GFM	18	5	14.6% inhibition at 10^-4M
4010	16722632	YA*GFM	18	5	38.4% inhibition at 10^-3M
4011	16722632	YA*GFM	18	5	17.7% inhibition at 10^-6M
4012	16722632	YA*GFM	18	5	10.9% inhibition at 10^-5M
4013	16722632	YA*GFM	18	5	12.1% inhibition at 10^-4M
4014	16722632	YA*GFM	18	5	8.1% inhibition at 10^-3M
4023	16722632	YGGFMA*	23	6	9.2% inhibition at 10^-3M
4024	16722632	YGGFMA*	23	6	11.08% inhibition at 10^-5M
4025	16722632	YGGFMA*	23	6	47.0% inhibition at 10^-3M
4032	12631273, 9266696	GLFDVIKKVASVIGGL	Citropin 1.1	16	IC₅₀= 5 M
4041	12631273, 9266696	glfdvikkvasviggl	Citropin 1.1D	16	IC₅₀= 5 M
4050	12631273, 9266696	GLFAVIKKVASVIGGL	3	16	IC₅₀= 6 M
4059	12631273, 9266696	GLFDVIKAVASVIGGL	5	16	IC₅₀= 5 M
4068	12631273, 9266696	GLFDVIKKVAAVIGGL	7	16	IC₅₀= 5 M
4077	12631273, 9266696	GLFDVIKKVASVIKGL	11	16	IC₅₀= 5 M
4086	12631273, 9266696	GLFDVIKKVASVIKKL	13	16	IC₅₀= 5 M
4095	12631273, 9266696	GLFDVIAKVASVIKKL	14	16	IC₅₀= 5 M
4104	12631273, 9266696	GLFAVIKKVASVIKGL	15	16	IC₅₀= 5 M
4113	12631273, 9266696	GLFAVIKKVASVIKKL	16	16	IC₅₀= 5 M
4122	12631273, 9266696	GLFAVIKKVAAVIKKL	17	16	IC₅₀= 5 M
4131	12631273, 9266696	GLFAVIKKVAAVIRRL	18	16	IC₅₀= 5 M
4140	12631273, 9266696	GLFAVIKKVAKVIKKL	19	16	IC₅₀= 5 M
4149	12631273, 9266696	GLFKVIKKVASVIGGL	22	16	IC₅₀= 5 M
4158	12631273, 9266696	GLFKVIKKVAKVIKKL	23	16	IC₅₀= 5 M
4167	12631273, 9266696	LGGIVSAVKKIVDFLG	retro	16	IC₅₀= >10 µM
4495	22057278	KAAKKWAKAAKKWAKAWKKAA	Z1	21	EC₅₀ >211 µM
4496	22057278	KAAKKWAKAWKKAAKAWKKAA	Z2	21	EC₅₀ >211 µM
4497	22057278	KAAKKAWKAWKKAAKAAWKKAA	Z3	21	EC₅₀ >211 µM
4498	22057278	KAAKKAWKAAKKAAKWWKKAA	Z4	21	EC₅₀ =173 µM
4499	22057278	KAAKKAWKWAKKAAKWAKKAA	Z5	21	EC₅₀ =67 µM
4500	22057278	KWWKKAAKAAKKAAKAAKKWA	Z6	21	EC₅₀ =31 µM
4501	22057278	KAAKKAWKAAKKAWKAAKKAA	Z7	21	EC₅₀ =21 µM
4502	22057278	AWKKWAKAWKWAKAKWWAKAA	Z8	21	EC₅₀ =23 µM
4503	22057278	AAWKWAWAKKWAKAKKWAKAA	Z9	21	EC₅₀ =13 µM
4504	22057278	AAKKWAKAKWAKAKKWAKAA	Z10	21	EC₅₀ >211 µM
4578	21423613	PRFWEYWLRLME	MIP	12	IC₅₀ =0.01 µM
4579	21423613	LTFEHYWAQLTS	DI	12	IC₅₀ =0.29 µM
4580	21423613	LTAEHYAAQATS	3A	12	IC₅₀ >100 µM
4581	21423613	QETFSDLWKLLP	P5317-28	12	IC₅₀ =4.7 µM
4582	21423613	PRAWEYWLRLME	MIP(F3A)	12	IC₅₀ =0.57 µM
4583	21423613	PRFWEAWLRLME	MIP(Y6A)	12	IC₅₀ >100 µM
4584	21423613	PRFWEYALRLME	MIP(W7A)	12	IC₅₀ >100 µM
4585	21423613	PRFWEYWLALME	MIP(R9A)	12	IC₅₀ =0.02 µM
4586	21423613	PRFWEYWLRAME	MIP(L10A)	12	IC₅₀ =1.14 µM
4587	21423613	PRFWEYWLRLAE	MIP(M11A)	12	IC₅₀ =0.4 µM
4588	21423613	PRFWEYWLRLME	MIP	12	IC₅₀ =0.12 µM
4589	21423613	LTFEHYWAQLTS	DI	12	IC₅₀ =1.6 µM
4590	21423613	LTAEHYAAQATS	3A	12	IC₅₀ >100 µM
4591	21423613	QETFSDLWKLLP	P5317-28	12	IC₅₀ =30 µM
5016	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >50% at 25μM approx
5017	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability =50% at 12.5μM approx.
5018	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >50% at 12.5μM approx.
5019	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >60% at 25μM approx
5020	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >50% at 25μM approx
5021	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >60% at 25μM approx
5022	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >60% at 25μM approx
5023	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >50% at 25μM approx
5024	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >50% at 25μM approx
5025	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >50% at 25μM approx
5026	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >50% at 25μM approx
5027	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >50% at 25μM approx
5028	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >60% at 25μM approx
5029	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability =50% at 12.5μM approx.
5030	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability =50% at 12.5μM approx.
5031	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >40% at 12.5μM approx
5032	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >40% at 12.5μM approx
5033	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >50% at 12.5μM approx
5034	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >55% at 12.5μM approx
5035	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >55% at 12.5μM approx
5036	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >75% at 12.5μM approx
5037	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >55% at 12.5μM approx
5038	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >55% at 12.5μM approx
5039	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >70% at 12.5μM approx
5040	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >45% at 12.5μM approx
5041	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >80% at 12.5μM approx
5042	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >85% at 12.5μM approx
5043	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >70% at 12.5μM approx
5044	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >60% at 12.5μM approx
5045	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >70% at 12.5μM approx
5046	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >80% at 12.5μM approx
5047	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >65% at 12.5μM approx
5048	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >70% at 12.5μM approx
5049	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >55% at 12.5μM approx
5050	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >80% at 12.5μM approx
5051	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >85% at 12.5μM approx
5052	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A	27	Cell viability >50% at 12.5μM approx
5053	24962950	KILRGVAKKIMRTFLRRISKKILTGKK	C7A-D21K	27	Cell viability >65% at 12.5μM approx
5054	24962950	KILRGVAKKIMRTFLRRISKDILTGKK	C7A-Δ	27	Cell viability >70% at 12.5μM approx
5056	24714081	TKPRKTKPRKTKPRKTKPR	T Peptide	19	70% maximum inhibitory rate at 8 mg/kg

CancerPPD :Database of Anticancer peptides and Proteins

Browse Result page of CancerPPD